01—Abstract
Summary
Summary of the 10-Q filed May 8, 2024. Cited figures are marked; the original filing is the authoritative source.
Pfizer Inc. (PFE) reported its first-quarter 2024 financial results, showing a notable decrease in total revenues to $14.9 billiona from $18.5 billion in the prior year period, a 20% decline driven primarily by lower sales of its COVID-19 products, Comirnaty and Paxlovid.
Excluding these, total revenues saw an operational increase of 11%, bolstered by the recent acquisition of Seagen, continued growth in the Vyndaqel family and Eliquis, and the launch of Abrysvo for older adults. Net income attributable to Pfizer Inc. common shareholders significantly decreased to $3.1 billionb, or $0.55 per diluted share, compared to $5.5 billion, or $0.97 per diluted share, in the first quarter of 2023. The company continues to manage its cost base, announcing a multi-year enterprise-wide cost realignment program expected to yield at least $4 billion in net cost savings by 2024.
Integration of the Seagen acquisition, which closed in December 2023, is ongoing and is expected to generate approximately $1 billionc in annual cost synergies by 2026. Pfizer also reported a substantial decrease in operating cash flow, alongside strategic actions such as the partial sale of its Haleon investment, generating $3.5 billion in proceeds.
02—Key points
Key Highlights
- Total revenues decreased by 20% year-over-year to $14.9 billion, primarily due to a significant decline in COVID-19 product sales (Comirnaty and Paxlovid).
- Excluding COVID-19 products, operational revenue increased by 11%, driven by contributions from the Seagen acquisition, growth in key products like Vyndaqel family and Eliquis, and new product launches such as Abrysvo.
- Net income attributable to Pfizer Inc. common shareholders fell to $3.1 billion ($0.55/share) from $5.5 billion ($0.97/share) in the prior year period.
- Operating cash flow decreased to $1.1 billion compared to $1.2 billion in Q1 2023.
- The company is executing a cost realignment program targeting at least $4 billion in savings by 2024 and is projecting $1 billion in annual synergies from the Seagen acquisition by 2026.
- Pfizer sold a portion of its investment in Haleon in March 2024, realizing $3.5 billion in proceeds.
- Significant patent litigation and regulatory reviews remain ongoing for key products, including COVID-19 vaccines and treatments.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2024filed May 8, 2024Financial Statements
| Revenue | $14.88B |
| Cost of Revenue | $3.38B |
| Gross Profit | $11.50B |
| SG&A Expenses | $3.50B |
| Interest Expense | $790.00M |
| Net Income | $3.12B |
| EPS (Basic) | $0.55 |
| EPS (Diluted) | $0.55 |
| Shares Outstanding (Basic) | 5.66B |
| Shares Outstanding (Diluted) | 5.70B |
05—Questions
Frequently Asked Questions
What is the primary reason for the significant decrease in Pfizer's revenue in Q1 2024 compared to Q1 2023?
The primary reason for the significant year-over-year revenue decrease is the substantial decline in sales of Pfizer's COVID-19 products, Comirnaty and Paxlovid. These products saw reduced demand and a transition from government contracts to traditional commercial market sales, leading to lower revenues.
How is Pfizer managing its costs and what are the expected savings?
Pfizer announced a multi-year, enterprise-wide cost realignment program aimed at aligning costs with long-term revenue expectations. This program is expected to deliver at least $4 billion in net cost savings by 2024. Additionally, integration of the Seagen acquisition is underway, with projected annual cost synergies of approximately $1 billion by 2026.
What impact has the acquisition of Seagen had on Pfizer's financial results?
The acquisition of Seagen, which closed in December 2023, contributed to revenue growth in the first quarter of 2024, particularly within the oncology segment. The company is also working on integrating Seagen to achieve cost synergies and expects this acquisition to be a key driver for its oncology leadership goal.
What is the current status of Pfizer's cash position and liquidity?
Pfizer's condensed consolidated balance sheet shows cash and cash equivalents of $719 million and short-term investments of $11.2 billion as of March 31, 2024. The company reported operating cash flow of $1.1 billion for the quarter. Pfizer states it believes it has the ability to meet its liquidity needs for the foreseeable future through operating cash flows, financial assets, and access to capital markets.
06—Continue